Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclobenzaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobenzaprine SCHEMBL7654526 | 1.00 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL38527 | 1.00 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29350662 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4964925 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL41376 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL1649752 | 0.97 | HRH1 (0.93) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4606463 | 0.97 | LMNA (0.97) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL17812696 | 0.92 | HRH1 (0.84) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29015268 | 0.91 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL8892591 | 0.91 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099345-A1 | LARCH TURPENTINE EMULSION | VEREIN FÜR KREBSFORSCHUNG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMA LTD (IE) | 2026-04-23 | — | — | US | disclosed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4626549-A1 | TREATMENT OF FIBROMYALGIA | UCB Biopharma SRL (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250288540-A1 | METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT | SILO PHARMA, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025160302-A1 | CYCLOBENZAPRINE TREATMENT FOR ACUTE STRESS REACTION OR ACUTE STRESS DISORDER | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2025-07-31 | — | — | WO | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022125572-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125572-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022109218-A1 | CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109218-A1 | CYCLOBENZAPRINE TREATMENT FOR ALCOHOL USE DISORDER | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022100614-A1 | BENZOUREA RING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京明德新药研发有限公司 | 2022-05-19 | — | — | WO | disclosed |
| WO-2022100614-A1 | BENZOUREA RING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京明德新药研发有限公司 | 2022-05-19 | — | — | WO | disclosed |
| US-11324732-B2 | Methods for the treatment of dyskinesia in cerebral palsy | AUSPEX PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022079092-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079091-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | FAAH, CRH, FUCA2 | HTR2A 32/4885HTR2C 81/4885HRH1 105/4885 |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | TNNI3, TNNC1, ATP2A3 | HTR2A 1426/4885HTR2C 953/4885HRH1 3095/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | HTR2A 3472/4885HTR2C 3971/4885HRH1 3627/4885 |
| US-11324732-B2 | Methods for the treatment of dyskinesia in cerebral palsy | DDO, GABBR1, CHAT | HTR2A 250/4885HTR2C 562/4885HRH1 1469/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | HTR2A 2738/4885HTR2C 857/4885HRH1 1375/4885 |
| US-20250288540-A1 | METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT | OPRK1, KYNU, KCNQ3 | HTR2A 218/4885HTR2C 312/4885HRH1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.